SCHEMBL838503

SCHEMBL838503

COC(=O)[C@H](CCSC)O[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.42
KMT2A Q03164 3/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
GAA P10253 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
FNTA P49354 2/20 0.36
FNTB P49356 2/20 0.36
TSHR P16473 2/20 0.36
POLB P06746 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
MIF P14174 1/20 0.36
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL838502 1.00 RECQL (0.42) RECQLKMT2ACYP3A4CYP2C19GAA
SCHEMBL839906 0.88 GAA (0.36) RECQLKMT2AGAAFNTAFNTB
SCHEMBL839905 0.88 GAA (0.36) RECQLKMT2AGAAFNTAFNTB
SCHEMBL23527747 0.84 HTR2A (0.40) KMT2ACYP3A4CYP2C19GAATSHR
SCHEMBL1806312 0.84 KMT2A (0.39) KMT2ATSHRMEN1ALDH1A1LMNA
SCHEMBL5970972 0.83 KMT2A (0.42) KMT2ATSHRMEN1ALDH1A1LMNA
SCHEMBL839799 0.81 HTT (0.39) RECQLKMT2ACYP2C19POLBALDH1A1
SCHEMBL839798 0.81 HTT (0.39) RECQLKMT2ACYP2C19POLBALDH1A1
SCHEMBL22029726 0.77 GPR88 (0.38) RECQLKMT2AL3MBTL1POLBMEN1
SCHEMBL30879112 0.76 KMT2A (0.46) RECQLKMT2AL3MBTL1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
EP-2324028-A2 THERAPEUTIC AGENTS 414 AstraZeneca AB (SE) 2011-05-25 EP disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 RECQL 3360/4885KMT2A 4136/4885CYP3A4 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.